Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Graft vs Host Disease 1

Interventions

venetoclax 12Cytarabine 12Azacitidine 10Decitabine 8Daunorubicin 7Cyclophosphamide 7Busulfan 6fludarabine phosphate 5Idarubicin 5Gemtuzumab 5Thiotepa 3Stem Cell Transplantation 3Filgrastim 3Cyclosporine 3vosaroxin 2fludarabine 2Whole-Body Irradiation 2Tretinoin 2Sorafenib 2Radiotherapy 2Methylprednisolone 2Methotrexate 2Melphalan 2Injections 2Etoposide 2Cladribine 2CPX-351 2Antilymphocyte Serum 2Abatacept 2vedolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Leukemia, Myeloid, Acute × vedolizumab × Clear all
NCT06475820 2024-08-23

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Active not recruiting
150 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡